<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078065</url>
  </required_header>
  <id_info>
    <org_study_id>XT005</org_study_id>
    <nct_id>NCT00078065</nct_id>
  </id_info>
  <brief_title>Xcellerated T CellsTM in Patients With Multiple Myeloma</brief_title>
  <official_title>A Randomized Phase II Study of Xcellerated T CellsTM With or Without Prior Fludarabine Therapy in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xcyte Therapies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xcyte Therapies</source>
  <brief_summary>
    <textblock>
      This trial is a phase II, randomized study of patients with multiple myeloma. All patients&#xD;
      will receive Xcellerated T Cells, with or without prior fludarabine therapy.&#xD;
&#xD;
      15 patients in each study arm will be followed for 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized Phase II clinical study is designed to examine the safety and efficacy of&#xD;
      Xcellerated T CellsTM, an activated, autologous T cell product, in subjects with multiple&#xD;
      myeloma. Subjects must have failed at least one, but no more than three, prior cytotoxic&#xD;
      therapies prior to study registration and may not have relapsed or progressed within one year&#xD;
      following hematopoietic stem cell transplantation. Patients will be randomized to treatment&#xD;
      with either Xcellerated T Cells alone, or lymphoablative therapy with fludarabine followed by&#xD;
      Xcellerated T Cells. Thirty subjects will be treated, with 15 patients in each arm. Patients&#xD;
      will be followed for six months following treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date>June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xcellerated T Cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Previous diagnosis of multiple myeloma (MM) based on standard criteria. Tests need not&#xD;
             be performed within 30 days of registration.&#xD;
&#xD;
          -  Failure of at least one, but no more than four, prior systemic therapies for MM prior&#xD;
             to registration and may not have relapsed or progressed within 1 year following&#xD;
             autologous hematopoietic stem cell transplantation. Repeat courses of the same&#xD;
             therapeutic regimen separated in time by 6 or more months are considered separate&#xD;
             therapies. Induction therapy followed by high dose chemotherapy and autologous&#xD;
             hematopoietic stem cell transplantation counts as one therapy.&#xD;
&#xD;
          -  Measurable serum and/or urine M-protein&#xD;
&#xD;
          -  Disease progression or relapse, since most recent therapy for multiple myeloma&#xD;
&#xD;
          -  Age &gt; 18 years old and &lt; 75 years old&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative serum bHCG test and be willing&#xD;
             to use effective contraception (i.e., a hormonal contraceptive, intra-uterine device,&#xD;
             diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of&#xD;
             the trial&#xD;
&#xD;
          -  Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2,&#xD;
             hepatitis B, and hepatitis C within 30 days of registration (Antibody, antigen, and&#xD;
             nucleic acid tests acceptable, depending on institutional standards)&#xD;
&#xD;
          -  Hemoglobin &gt;= 10.0 g/dL. Transfusion with red blood cells or use of erythropoietin is&#xD;
             permissible.&#xD;
&#xD;
          -  White blood count (WBC) &gt;= 3,000/mm3 and absolute neutrophil count (ANC) &gt; 1000/mm3&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm3&#xD;
&#xD;
          -  Corrected serum calcium &lt; 11 mg/dL, and no evidence of symptomatic hypercalcemia.&#xD;
             (Corrected serum calcium is calculated by adding 0.8 mg/dL to the measured serum&#xD;
             calcium for every 1 g/dL that the serum albumin falls below 4.0 g/dL)&#xD;
&#xD;
          -  Serum total bilirubin and alanine aminotransferase (ALT) &lt; 2.0 times the upper limit&#xD;
             of normal&#xD;
&#xD;
          -  Serum creatinine &lt; 2.5 mg/dL&#xD;
&#xD;
          -  Serum human anti-mouse antibody (HAMA) titer undetectable or within the normal range,&#xD;
             and no history of allergies to mice or murine (mouse) proteins&#xD;
&#xD;
          -  The patient must be able to comprehend and have signed the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W Frohlich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xcyte Therapies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncotherapeutics</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer &amp; Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>February 18, 2004</study_first_submitted>
  <study_first_submitted_qc>February 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2004</study_first_posted>
  <last_update_submitted>November 10, 2005</last_update_submitted>
  <last_update_submitted_qc>November 10, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2005</last_update_posted>
  <keyword>multiple myeloma</keyword>
  <keyword>fludarabine</keyword>
  <keyword>Xcellerated T Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

